Healthcare / BiotechnologyParis
$1.23
+0.00 (+0.16%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-12.0M · quality 58.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$17M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-144.9%
↓Gross Margin
N/A
•Debt/Equity
1.49
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.83x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-6.4M · FCF $-5.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $2.7M | $9.1M | $3.8M |
| Net Income | $-6.4M | $-6.4M | $-7.5M | $-5.1M | $-14.3M |
| EBITDA | $-5.6M | $-5.6M | $-6.7M | $-4.6M | $-14.0M |
| EPS | -0.47 | -0.47 | -0.55 | -0.39 | -1.21 |
| Operating Margin | — | — | -288.8% | -71.4% | -223.8% |
| Net Margin | — | — | -278.4% | -56.1% | -375.1% |
| Balance Sheet | |||||
| Debt/Equity | 1.49 | 1.49 | 0.60 | 0.31 | 0.19 |
| Current Ratio | 4.40 | 4.40 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-5.4M | $-5.4M | $-12.0M | $-13.0M | $-13.2M |
| Returns | |||||
| ROE | -144.9% | -144.9% | -73.7% | -38.5% | -72.2% |
| Valuation | |||||
| P/B | 3.78 | 3.78 | 2.88 | 13.28 | 8.12 |
| Growth & Yield | |||||
| Revenue Growth | — | — | -70.4% | 137.7% | — |
| EPS Growth | 13.8% | 13.8% | -42.1% | 68.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+4.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.55 → -0.47
Residual
+4.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.